- Home
- MNSB vs GLSI Comparison
MNSB vs GLSI Comparison
Compare MNSB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- GLSI
- Stock Information
- Founded
- MNSB 2003
- GLSI 2006
- Country
- MNSB United States
- GLSI United States
- Employees
- MNSB N/A
- GLSI N/A
- Industry
- MNSB Major Banks
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- MNSB Finance
- GLSI Health Care
- Exchange
- MNSB Nasdaq
- GLSI Nasdaq
- Market Cap
- MNSB 140.7M
- GLSI 133.4M
- IPO Year
- MNSB N/A
- GLSI 2020
- Fundamental
- Price
- MNSB $18.30
- GLSI $8.90
- Analyst Decision
- MNSB
- GLSI Strong Buy
- Analyst Count
- MNSB 0
- GLSI 1
- Target Price
- MNSB N/A
- GLSI $39.00
- AVG Volume (30 Days)
- MNSB 23.4K
- GLSI 33.7K
- Earning Date
- MNSB 07-28-2025
- GLSI 08-13-2025
- Dividend Yield
- MNSB 2.17%
- GLSI N/A
- EPS Growth
- MNSB N/A
- GLSI N/A
- EPS
- MNSB N/A
- GLSI N/A
- Revenue
- MNSB $59,896,000.00
- GLSI N/A
- Revenue This Year
- MNSB $17.95
- GLSI N/A
- Revenue Next Year
- MNSB $2.52
- GLSI N/A
- P/E Ratio
- MNSB N/A
- GLSI N/A
- Revenue Growth
- MNSB N/A
- GLSI N/A
- 52 Week Low
- MNSB $15.00
- GLSI $8.06
- 52 Week High
- MNSB $20.88
- GLSI $18.15
- Technical
- Relative Strength Index (RSI)
- MNSB 45.27
- GLSI 35.87
- Support Level
- MNSB $18.00
- GLSI $9.40
- Resistance Level
- MNSB $18.52
- GLSI $9.92
- Average True Range (ATR)
- MNSB 0.46
- GLSI 0.29
- MACD
- MNSB -0.07
- GLSI -0.07
- Stochastic Oscillator
- MNSB 24.65
- GLSI 0.00
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.